Entrada Therapeutics rises on UK approval for muscle-wasting drug study

Entrada Therapeutics

24/03/2025 14:39

** Drug developer Entrada Therapeutics' TRDA.O shares rise 2.5% to $10.75

** Company says it has received authorization from UK's regulatory agency to begin an early-stage study for an experimental drug, ENTR-601-45, for potential treatment of Duchenne muscular dystrophy, a type of muscle-wasting disorder

** Entrada says it is on track to start study in Q3 2025

** Company's shares have fallen 22.5% in past 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))